Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)Akira Inoue, T. Nukiwa, Kunihiko Kobayashi et al.|Annals of Oncology|2012Cited by 555
Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902Shunichi Sugawara, T. Nukiwa, Satoshi Oizumi et al.|Annals of Oncology|2015Cited by 111
Phase III study of gefitinib (G) versus gefitinib+carboplatin+pemetrexed (GCP) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009)Masahiro Seike, T. Nukiwa, A. Inoue et al.|Annals of Oncology|2018Cited by 10
[A case of secondary amyloidosis which gastrointestinal symptoms improved by treatment with salazosulfapyridine].Yuichiro Matsuoka, Hisanori Miura, Shigefumi OKAMOTO et al.|PubMed|1991Cited by 1